Background Clinical trial data are scarce for the use of prophylaxis in people with non-severe
haemophilia A. The HAVEN 6 study aims to assess safety and efficacy of emicizumab …

Objective Individuals with deficiency of adenosine deaminase 2 ( DADA 2), a recently recognized
autosomal recessive disease, present with various systemic vascular and inflammatory …

Extracellular vesicles (EVs) are nanosized membrane-bound particles released from all living
cells examined thus far. EVs can transfer information in the form of proteins, nucleic acids, …

Objective Our objective was to generate, optimize, and validate a self‐administered
pediatric bleeding questionnaire (Self‐PBQ) as a screening tool for von Willebrand disease (VWD) …

Inflammatory signals such as pathogen- and danger-associated molecular patterns have
been hypothesized as risk factors for the initiation of the anti–factor VIII (FVIII) immune …

Background: Emicizumab, a bispecific monoclonal antibody, bridges activated factor (F)IX
and FX, substituting for the function of missing activated FVIII in persons with hemophilia A (HA…

Newborns with hemophilia are at risk of intracranial hemorrhage, extracranial hemorrhage,
and other bleeding complications. The safe delivery of a healthy newborn with hemophilia is …

… Devonne Ryan and Paul Moorehead recruited the participants. … Paul Moorehead confirmed
the data analysis. Devonne Ryan drafted the manuscript. Roger Chafe and Paul Moorehead …

Purpose This systematic review summarizes the evidence for the effectiveness of interventions
aimed at improving the experiences and outcomes for childhood cancer survivors (CCS). …

Pediatric B-acute lymphoblastic leukemia (B-ALL) is a disease of abnormally growing B
lymphoblasts. Here we hypothesized that extracellular vesicles (EVs), which are nanosized …